col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

438 Results       Page 1

Springer-Verlag: Reactions Weekly
  original article Date Title Authors   All Authors
1 [GO] 2022―Jun―23 Acute neurological AEs after COVID-19 vaccination
2 [GO] 2022―Jun―23 COVID-19 vaccination and risk of neuralgic amyotrophy
3 [GO] 2022―Jun―23 COVID-19 vaccination relatively safe in autoimmune diseases
4 [GO] 2022―Jun―23 COVID-19 vaccines/mycophenolate mofetil
5 [GO] 2022―Jun―23 Sars-cov-2-vaccine-inactivated
6 [GO] 2022―Jun―23 Sars-cov-2-vaccine-inactivated-sinovac-biotech
7 [GO] 2022―Jun―23 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
8 [GO] 2022―Jun―23 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
9 [GO] 2022―Jun―17 Risk of myocarditis or pericarditis after COVID-19 mRNA vaccines
10 [GO] 2022―Jun―17 Risk of Guillain-Barre Syndrome after COVID-19 vaccination
11 [GO] 2022―Jun―17 Janssen COVID-19 vaccine increases risk of thrombocytopenia
12 [GO] 2022―Jun―17 COVID-19 vaccine-Pfizer-BioNTech
13 [GO] 2022―Jun―17 Covid-19-vaccine first report
14 [GO] 2022―Jun―17 Covid-19-vaccine-pfizer-biontech
15 [GO] 2022―Jun―17 SARS-COV-2-vaccine-inactivated Sinovac-Biotech
16 [GO] 2022―Jun―17 Sars-cov-2-vaccine-inactivated-sinovac-biotech
17 [GO] 2022―Jun―17 Sars-cov-2-vaccine-inactivated-sinovac-biotech
18 [GO] 2022―Jun―10 AEs after homologous versus heterologous COVID-19 booster
19 [GO] 2022―Jun―10 Standardised assessment of COVID-19 vaccine-related skin reactions
20 [GO] 2022―Jun―10 Safety of mRNA COVID-19 vaccines during pregnancy
21 [GO] 2022―Jun―10 Covid-19-vaccine/lamotrigine
22 [GO] 2022―Jun―03 Low risk of myopericarditis after COVID-19 vaccination in children aged 5-11 years
23 [GO] 2022―Jun―03 Pfizer-BioNTech COVID-19 vaccine safe with clozapine
24 [GO] 2022―Jun―03 COVID-19 vaccine-induced VITT/TSS in Malaysia
25 [GO] 2022―Jun―03 Lareb study on COVID-19 vaccine-related menstrual disorders
26 [GO] 2022―Jun―03 COVID-19-vaccine
27 [GO] 2022―Jun―03 COVID-19-vaccine
28 [GO] 2022―Jun―03 COVID-19-Vaccine-Pfizer-BioNTech
29 [GO] 2022―Jun―03 Covid-19-vaccine-pfizer-biontech
30 [GO] 2022―Jun―03 COVID-19-vaccine-Pfizer-BioNtech
31 [GO] 2022―Jun―03 COVID-19-vaccine/SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran
32 [GO] 2022―Jun―03 Sars-cov-2-vaccine-inactivated-sinovac-biotech
33 [GO] 2022―Jun―03 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
34 [GO] 2022―Jun―03 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran
35 [GO] 2022―May―27 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
36 [GO] 2022―May―27 Fourth-dose boosters with COVID-19 mRNA vaccines well tolerated
37 [GO] 2022―May―27 Pfizer-BioNTech COVID-19 vaccine safe in children
38 [GO] 2022―May―27 Covid-19-vaccine
39 [GO] 2022―May―27 Covid-19-vaccine
40 [GO] 2022―May―27 Covid-19-vaccine
41 [GO] 2022―May―27 Covid-19-vaccine-pfizer-biontech
42 [GO] 2022―May―27 Covid-19-vaccine-pfizer-biontech/elasomeran
43 [GO] 2022―May―20 ADRs due to off-label use of hydroxychloroquine for COVID-19
44 [GO] 2022―May―20 Survey of adverse events following ChAdOx1 COVID-19 vaccination in Ethiopia
45 [GO] 2022―May―20 COVID-19-vaccine
46 [GO] 2022―May―20 Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology/immunosuppressants
47 [GO] 2022―May―20 COVID-19-Vaccine-Pfizer-BioNTech
48 [GO] 2022―May―20 Covid-19-vaccine-pfizer-biontech
49 [GO] 2022―May―20 Covid-19-vaccine-pfizer-biontech/levothyroxine-sodium/sars-cov-2-vaccine-inactivated-sinovac-biotech
50 [GO] 2022―May―20 COVID-19-vaccines/budesonide/mesalazine
51 [GO] 2022―May―13 FDA limits authorised use of Janssen COVID-19 vaccine
52 [GO] 2022―May―13 Covid-19-vaccine-pfizer-biontech
53 [GO] 2022―May―13 COVID-19-Vaccine-Pfizer-BioNTech
54 [GO] 2022―May―13 Covid-19-vaccine-pfizer-biontech
55 [GO] 2022―May―13 COVID-19-vaccine/plasma
56 [GO] 2022―May―13 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
57 [GO] 2022―May―06 COVID-19 vaccination may reactivate varicella-zoster virus
58 [GO] 2022―May―06 COVID-19-Vaccine-Pfizer-BioNTech
59 [GO] 2022―May―06 COVID-19-Vaccine-Pfizer-BioNTech
60 [GO] 2022―Apr―29 No increased risk for venous thromboembolism after COVID-19 vaccination
61 [GO] 2022―Apr―29 Safety profile of mRNA vaccines during first 6 months of the US COVID-19 vaccination programme reviewed
62 [GO] 2022―Apr―29 COVID-19 vaccine Gamaleya National Research Center of Epidemiology and Microbiology
63 [GO] 2022―Apr―29 COVID-19 Vaccine Pfizer BioNTech
64 [GO] 2022―Apr―29 Covid-19-vaccine
65 [GO] 2022―Apr―29 COVID-19-Vaccine-Pfizer-BioNTech/pegfilgrastim/pembrolizumab
66 [GO] 2022―Apr―29 Covid-19-vaccine/methylprednisolone
67 [GO] 2022―Apr―29 COVID-19-vaccine/mycophenolate
68 [GO] 2022―Apr―22 Cardiac risks higher after COVID-19 infection than mRNA vaccine
69 [GO] 2022―Apr―22 Lopinavir/ritonavir delays COVID-19 recovery in paediatric patients
70 [GO] 2022―Apr―22 PRAC meeting highlights April 2022: no link between mRNA COVID-19 vaccines and autoimmune hepatitis
71 [GO] 2022―Apr―22 Covid-19-vaccine
72 [GO] 2022―Apr―22 Covid-19-vaccine-pfizer-biontech
73 [GO] 2022―Apr―22 COVID-19-Vaccine-Pfizer-BioNTech
74 [GO] 2022―Apr―22 COVID-19-Vaccine-Pfizer-BioNTech/elasomeran
75 [GO] 2022―Apr―22 Covid-19-vaccine-pfizer-biontech/prednisone/valaciclovir
76 [GO] 2022―Apr―22 COVID-19-vaccines/immune-globulin/methylprednisolone
77 [GO] 2022―Apr―22 Coronavirus-vaccine
78 [GO] 2022―Apr―14 Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology
79 [GO] 2022―Apr―14 Covid-19-vaccine-pfizer-biontech
80 [GO] 2022―Apr―14 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
81 [GO] 2022―Apr―14 Sars-cov-2-vaccine-inactivated-sinovac-biotech
82 [GO] 2022―Apr―08 Remdesivir does not increase risk of AKI or ALI in COVID-19 patients
83 [GO] 2022―Apr―08 COVID-19 vaccine-Pfizer-BioNTech/methylprednisolone aceponate
84 [GO] 2022―Apr―08 No evidence of adverse neurological outcomes from COVID-19 vaccines
85 [GO] 2022―Apr―08 Covid-19-vaccine
86 [GO] 2022―Apr―08 COVID-19-vaccine
87 [GO] 2022―Apr―08 Covid-19-vaccine
88 [GO] 2022―Apr―08 Covid-19-vaccine-pfizer-biontech
89 [GO] 2022―Apr―08 Covid-19-vaccine-pfizer-biontech
90 [GO] 2022―Apr―08 COVID-19-Vaccine-Pfizer-BioNTech
91 [GO] 2022―Apr―08 COVID-19-Vaccine-Pfizer-BioNTech
92 [GO] 2022―Apr―08 Covid-19-vaccine/evolocumab
93 [GO] 2022―Apr―08 Sars-cov-2-vaccine-inactivated-sinovac-biotech
94 [GO] 2022―Apr―08 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
95 [GO] 2022―Apr―01 No safety signal after COVID-19 vaccination for immune-mediated neurological events
96 [GO] 2022―Apr―01 Myocarditis after third dose of Pfizer-BioNTech COVID-19 vaccine
97 [GO] 2022―Apr―01 COVID-19-vaccine
98 [GO] 2022―Apr―01 Covid-19-vaccine
99 [GO] 2022―Apr―01 COVID-19-Vaccine-Pfizer-BioNTech
100 [GO] 2022―Apr―01 Covid-19-vaccine-pfizer-biontech
101 [GO] 2022―Apr―01 Covid-19-vaccine-pfizer-biontech
102 [GO] 2022―Apr―01 Covid-19-vaccine-pfizer-biontech/ibuprofen/paracetamol/meloxicam
103 [GO] 2022―Apr―01 Best regimen for elexacaftor/ivacaftor/tezacaftor with nirmatrelvir-ritonavir for COVID-19?
104 [GO] 2022―Mar―25 Systemic AEs common after COVID-19 vaccination
105 [GO] 2022―Mar―25 COVID-19 vaccine Gamaleya National Research Center of Epidermiology and Microbiology
106 [GO] 2022―Mar―25 Covid-19 vaccine-Pfizer-BioNtech
107 [GO] 2022―Mar―25 Covid-19-vaccine
108 [GO] 2022―Mar―25 Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology/fexofenadine
109 [GO] 2022―Mar―25 Covid-19-vaccine-pfizer-biontech
110 [GO] 2022―Mar―25 Covid-19-vaccine-pfizer-biontech
111 [GO] 2022―Mar―25 Covid-19-vaccine-pfizer-biontech/sars-cov-2-vaccine-inactivated-sinovac-biotech
112 [GO] 2022―Mar―25 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
113 [GO] 2022―Mar―19 Covid-19-vaccine-pfizer-biontech
114 [GO] 2022―Mar―19 COVID-19-Vaccine-Pfizer-BioNTech/elasomeran
115 [GO] 2022―Mar―19 Sars-cov-2-vaccine-inactivated-sinovac-biotech
116 [GO] 2022―Mar―19 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
117 [GO] 2022―Mar―19 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
118 [GO] 2022―Mar―11 Covid-19-vaccine-pfizer-biontech
119 [GO] 2022―Mar―11 Covid-19-vaccine-pfizer-biontech/elasomeran
120 [GO] 2022―Mar―11 Coronavirus-vaccine
121 [GO] 2022―Mar―11 Coronavirus-vaccine-stemirna-therapeutics/tongji-university
122 [GO] 2022―Mar―05 Health Canada: risk of accidental poisoning from COVID-19 rapid antigen test kits
123 [GO] 2022―Mar―05 COVID-19-Vaccine-Pfizer-BioNTech
124 [GO] 2022―Mar―05 COVID-19-Vaccine-Pfizer-BioNTech
125 [GO] 2022―Mar―05 COVID-19-vaccine-pfizer-biontech
126 [GO] 2022―Mar―05 COVID-19-Vaccine-Pfizer-BioNTech
127 [GO] 2022―Mar―05 COVID-19-Vaccine-Pfizer-BioNTech
128 [GO] 2022―Mar―05 Covid-19-vaccine-pfizer-biontech
129 [GO] 2022―Mar―05 COVID-19-Vaccine-Pfizer-BioNTech
130 [GO] 2022―Mar―05 Covid-19-vaccine-pfizer-biontech
131 [GO] 2022―Mar―05 Covid-19-vaccine-pfizer-biontech/omalizumab
132 [GO] 2022―Mar―05 Covid-19-vaccine/vildagliptin interaction
133 [GO] 2022―Mar―05 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran
134 [GO] 2022―Feb―25 COVID-19 vaccine
135 [GO] 2022―Feb―25 COVID-19 vaccine
136 [GO] 2022―Feb―25 COVID-19 vaccine
137 [GO] 2022―Feb―25 Covid-19-vaccine
138 [GO] 2022―Feb―25 Covid-19-vaccine-pfizer-biontech
139 [GO] 2022―Feb―25 Covid-19-vaccine-pfizer-biontech
140 [GO] 2022―Feb―25 COVID-19-Vaccine-Pfizer-BioNTech/epinephrine
141 [GO] 2022―Feb―18 Increase in thromboembolic ADRs from oral contraceptives during COVID-19 pandemic in Spain
142 [GO] 2022―Feb―18 No adverse effects found for prenatal exposure to mRNA COVID-19 vaccine
143 [GO] 2022―Feb―18 COVID-19 Vaccine Pfizer BioNTech
144 [GO] 2022―Feb―18 COVID-19 Vaccine Pfizer BioNTech
145 [GO] 2022―Feb―18 COVID-19-Vaccine-Pfizer-BioNTech
146 [GO] 2022―Feb―18 COVID-19-Vaccine-Pfizer-BioNTech
147 [GO] 2022―Feb―18 Coronavirus-vaccine
148 [GO] 2022―Feb―18 Sars-cov-2-vaccine-inactivated-sinovac-biotech
149 [GO] 2022―Feb―11 mRNA COVID-19 vaccines safe in patients with previous COVID-19 infections
150 [GO] 2022―Feb―11 COVID-19 vaccine errors dominate ISMP's list of top 10 safety concerns for 2021
151 [GO] 2022―Feb―11 Covid-19-vaccine-pfizer-biontech
152 [GO] 2022―Feb―11 COVID-19-Vaccine-Pfizer-BioNTech
153 [GO] 2022―Feb―11 Covid-19-vaccine-pfizer-biontech
154 [GO] 2022―Feb―11 COVID-19-Vaccine-Pfizer-BioNTech
155 [GO] 2022―Feb―11 COVID-19-Vaccine-Pfizer-BioNTech
156 [GO] 2022―Feb―11 COVID-19-Vaccine-Pfizer-BioNTech
157 [GO] 2022―Feb―11 Sars-cov-2-vaccine-inactivated-sinovac-biotech
158 [GO] 2022―Feb―04 Younger males at greatest risk of myocarditis after mRNA-based COVID-19 vaccination
159 [GO] 2022―Feb―04 COVID-19 vaccine
160 [GO] 2022―Feb―04 Growing evidence reassuring for mRNA COVID-19 vaccines in pregnancy
161 [GO] 2022―Feb―04 COVID-19-vaccine
162 [GO] 2022―Feb―04 Covid-19-vaccine
163 [GO] 2022―Feb―04 Covid-19-vaccine
164 [GO] 2022―Jan―28 Reported rates of CVST due to COVID-19 vaccination rose after publicising these ADRs
165 [GO] 2022―Jan―28 Ad26.COV2.S COVID-19 vaccine: TTS a rare, but serious adverse event
166 [GO] 2022―Jan―28 Covid-19-vaccine-pfizer-biontech
167 [GO] 2022―Jan―28 Covid-19-vaccine-pfizer-biontech
168 [GO] 2022―Jan―28 Covid-19-vaccine-pfizer-biontech
169 [GO] 2022―Jan―28 COVID-19-Vaccine-Pfizer-BioNTech
170 [GO] 2022―Jan―28 COVID-19-Vaccine-Pfizer-BioNTech
171 [GO] 2022―Jan―28 Coronavirus-vaccine
172 [GO] 2022―Jan―28 Coronavirus-vaccine
173 [GO] 2022―Jan―21 COVID-19 vaccines safe in people living with HIV
174 [GO] 2022―Jan―21 SARS-COV-2 vaccine inactivated Sinovac Biotech
175 [GO] 2022―Jan―21 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
176 [GO] 2022―Jan―21 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
177 [GO] 2022―Jan―21 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
178 [GO] 2022―Jan―14 Casirivimab/imdevimab lack of efficacy against COVID-19 Omicron variant
179 [GO] 2022―Jan―14 Rare reports of rheumatic disorder flares after COVID-19 vaccination
180 [GO] 2022―Jan―14 Small change in menstrual cycle length after COVID-19 vaccination
181 [GO] 2022―Jan―14 Expected rates of adverse events after COVID-19 vaccination in USA
182 [GO] 2022―Jan―14 Covid-19-vaccine/tozinameran
183 [GO] 2022―Jan―14 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran
184 [GO] 2022―Jan―06 Low rate of myocarditis/pericarditis after COVID-19 mRNA vaccines
185 [GO] 2022―Jan―06 COVID-19 Vaccine Pfizer BioNTech
186 [GO] 2022―Jan―06 Signal for COVID-19 vaccine-related menstrual disorders
187 [GO] 2022―Jan―06 Systematic review: COVID-19 vaccine-related neurological disorders "exceedingly" rare
188 [GO] 2022―Jan―06 COVID-19-vaccine
189 [GO] 2022―Jan―06 COVID-19-vaccine
190 [GO] 2022―Jan―06 COVID-19-vaccine
191 [GO] 2022―Jan―06 COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology
192 [GO] 2022―Jan―06 COVID-19-Vaccine-Pfizer-BioNTech
193 [GO] 2022―Jan―06 Covid-19-vaccine-pfizer-biontech
194 [GO] 2022―Jan―06 COVID-19-Vaccine-Pfizer-BioNTech
195 [GO] 2022―Jan―06 Covid-19-vaccine-pfizer-biontech
196 [GO] 2022―Jan―06 Covid-19-vaccine-pfizer-biontech
197 [GO] 2022―Jan―06 Covid-19-vaccine/influenza-virus-vaccine
198 [GO] 2022―Jan―06 Covid-19-vaccine/mrna-1273
199 [GO] 2022―Jan―06 SARS-COV-2 vaccine inactivated-Sinovac-Biotech
200 [GO] 2022―Jan―06 Sars-cov-2-vaccine-inactivated-sinovac-biotech
201 [GO] 2022―Jan―06 Sars-cov-2-vaccine-inactivated-sinovac-biotech
202 [GO] 2022―Jan―06 Sars-cov-2-vaccine-inactivated-sinovac-biotech
203 [GO] 2021―Dec―18 COVID-19 Vaccine Pfizer-BioNTech
204 [GO] 2021―Dec―18 Most adolescent myocarditis cases related to covid-19 vaccines mild, resolve quickly
205 [GO] 2021―Dec―18 Covid-19-vaccine-pfizer-biontech
206 [GO] 2021―Dec―18 COVID-19-Vaccine-Pfizer-BioNTech
207 [GO] 2021―Dec―18 Coronavirus vaccine
208 [GO] 2021―Dec―18 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
209 [GO] 2021―Dec―18 Sars-cov-2-vaccine-inactivated-sinovac-biotech
210 [GO] 2021―Dec―10 Safety of seven COVID-19 vaccine booster doses
211 [GO] 2021―Dec―10 Myocarditis, pericarditis with COVID-19 vaccines in the Netherlands
212 [GO] 2021―Dec―10 COVID-19 vaccines/rituximab
213 [GO] 2021―Dec―10 COVID-19-Vaccine-Pfizer-BioNTech
214 [GO] 2021―Dec―10 COVID-19-Vaccine-Pfizer-BioNTech
215 [GO] 2021―Dec―10 Covid-19-vaccine/immune-globulin/methylprednisolone
216 [GO] 2021―Dec―10 COVID-19-vaccines
217 [GO] 2021―Dec―10 Covid-19-vaccines/rituximab
218 [GO] 2021―Dec―10 Sars-cov-2-vaccine-inactivated-sinovac-biotech
219 [GO] 2021―Dec―10 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
220 [GO] 2021―Dec―04 Risk-benefit of AstraZeneca COVID-19 vaccination in Australia
221 [GO] 2021―Dec―04 No increase in stroke, MI or PE after Pfizer-BioNTech COVID-19 vaccine
222 [GO] 2021―Dec―04 Adverse reactions with Pfizer/BioNTech's COVID-19 vaccine in Ecuador
223 [GO] 2021―Dec―04 Pfizer-BioNTech COVID-19 vaccine safe in older Koreans
224 [GO] 2021―Dec―04 COVID-19-vaccine
225 [GO] 2021―Dec―04 COVID-19-Vaccine-Pfizer-BioNTech
226 [GO] 2021―Dec―04 Covid-19-vaccine-pfizer-biontech
227 [GO] 2021―Dec―04 Covid-19-vaccine-pfizer-biontech
228 [GO] 2021―Dec―04 COVID-19-Vaccine-Pfizer-BioNTech/mRNA-1273
229 [GO] 2021―Dec―04 Coronavirus-vaccine
230 [GO] 2021―Dec―04 Coronavirus-vaccine-Wuhan-Institute-of-Biological-Products
231 [GO] 2021―Nov―26 Cutaneous vasculitis following COVID-19 vaccination
232 [GO] 2021―Nov―26 COVID-19 vaccine Pfizer BioNTech
233 [GO] 2021―Nov―26 Possibility of mix-up with paediatric COVID-19 vaccines
234 [GO] 2021―Nov―26 COVID-19-Vaccine-Pfizer-BioNTech
235 [GO] 2021―Nov―26 Covid-19-vaccine-pfizer-biontech
236 [GO] 2021―Nov―26 Covid-19-vaccine-pfizer-biontech
237 [GO] 2021―Nov―19 Myocarditis rare after COVID-19 mRNA vaccination
238 [GO] 2021―Nov―19 Increased risk of immune thrombocytopenia following AstraZeneca Covid-19 vaccine
239 [GO] 2021―Nov―19 English-only labels for Janssen's COVID-19 vaccine in Canada
240 [GO] 2021―Nov―19 COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology
241 [GO] 2021―Nov―19 Covid-19-vaccine-pfizer-biontech
242 [GO] 2021―Nov―19 Covid-19-vaccine-pfizer-biontech
243 [GO] 2021―Nov―19 COVID-19-Vaccine-Pfizer-BioNTech
244 [GO] 2021―Nov―19 Covid-19-vaccine-pfizer-biontech
245 [GO] 2021―Nov―19 COVID-19-vaccine-pfizer-biontech/ibuprofen/oxycodone
246 [GO] 2021―Nov―19 Covid-19-vaccine-Pfizer-BioNTech/mRNA-1273
247 [GO] 2021―Nov―05 COVID-19 vaccine
248 [GO] 2021―Nov―05 COVID-19-Vaccine-Pfizer-BioNTech
249 [GO] 2021―Nov―05 Covid-19-vaccine-pfizer-biontech
250 [GO] 2021―Nov―05 Covid-19-vaccine-pfizer-biontech
251 [GO] 2021―Nov―05 COVID-19-Vaccine-Pfizer-BioNTech
252 [GO] 2021―Nov―05 Covid-19-vaccine-pfizer-biontech
253 [GO] 2021―Nov―05 COVID-19-Vaccine-Pfizer-BioNTech
254 [GO] 2021―Nov―05 COVID-19-Vaccine-Pfizer-BioNTech/mRNA-1273
255 [GO] 2021―Nov―05 COVID-19-Vaccine-Pfizer-BioNTech/mycophenolic acid/tacrolimus
256 [GO] 2021―Nov―05 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
257 [GO] 2021―Oct―29 Covid-19-vaccine-pfizer-biontech
258 [GO] 2021―Oct―29 COVID-19-Vaccine-Pfizer-BioNTech
259 [GO] 2021―Oct―29 Covid-19-vaccine/rituximab
260 [GO] 2021―Oct―22 COVID-19-Vaccine-Pfizer-BioNTech
261 [GO] 2021―Oct―22 Covid-19-vaccine-pfizer-biontech
262 [GO] 2021―Oct―22 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
263 [GO] 2021―Oct―16 Pfizer-BioNTech COVID-19 vaccine in patients with severe allergies
264 [GO] 2021―Oct―16 Covid-19-vaccine
265 [GO] 2021―Oct―16 COVID-19-vaccine
266 [GO] 2021―Oct―16 COVID-19-Vaccine-Pfizer-BioNTech
267 [GO] 2021―Oct―16 SARS-COV-2 vaccine inactivated Sinovac Biotech
268 [GO] 2021―Oct―16 No evidence of birth defects or spontaneous abortion from pandemic H1N1-influenza vaccine
269 [GO] 2021―Oct―10 Covid-19 vaccine-Pfizer-Biontech
270 [GO] 2021―Oct―10 No association between COVID-19 vaccination and menstrual disorders
271 [GO] 2021―Oct―01 FAPIC score predicts mortality after COVID-19 vaccine-related TTS
272 [GO] 2021―Oct―01 Product monographs for COVID-19 vaccines updated in Canada
273 [GO] 2021―Oct―01 Covid-19-vaccine-pfizer-biontech
274 [GO] 2021―Oct―01 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
275 [GO] 2021―Sep―24 COVID-19 vaccination safe during pregnancy
276 [GO] 2021―Sep―24 Covid-19-vaccine-pfizer-biontech
277 [GO] 2021―Sep―17 Minimal risk of GBS relapse after Pfizer-BioNTech COVID-19 vaccination
278 [GO] 2021―Sep―17 COVID-19-Vaccine-Pfizer-BioNTech
279 [GO] 2021―Sep―17 COVID-19-Vaccine-Pfizer-BioNTech/ciclosporin/mycophenolate sodium
280 [GO] 2021―Sep―17 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
281 [GO] 2021―Sep―12 Warnings of risks associated with ivermectin use for COVID-19
282 [GO] 2021―Sep―12 mRNA-based vs viral vector-based COVID-19 vaccines
283 [GO] 2021―Sep―12 Covid-19-vaccine-pfizer-biontech
284 [GO] 2021―Sep―12 COVID-19-Vaccine-Pfizer-BioNTech
285 [GO] 2021―Sep―12 Coronavirus-vaccine-stemirna-therapeutics/tongji-university
286 [GO] 2021―Sep―12 SARS-COV-2-vaccine-inactivated-Sinovac-Biotech
287 [GO] 2021―Sep―04 Antihypertensives: sex differences in risk of COVID-19
288 [GO] 2021―Sep―04 Thrombocytopenia and thromboembolism after COVID-19 vaccination
289 [GO] 2021―Sep―04 COVID-19 Vaccine Pfizer BioNTech
290 [GO] 2021―Sep―04 AstraZeneca COVID-19 vaccine-related thrombocytopenia and thrombosis
291 [GO] 2021―Sep―04 Covid-19-vaccine-Pfizer-BioNTech
292 [GO] 2021―Sep―04 Covid-19-vaccine-pfizer-biontech
293 [GO] 2021―Sep―04 Covid-19-vaccine-pfizer-biontech
294 [GO] 2021―Sep―04 Convalescent anti SARS-CoV-2 plasma/norepinephrine/tocilizumab
295 [GO] 2021―Aug―27 Covid-19 vaccine pfizer biontech
296 [GO] 2021―Aug―27 Teen COVE study finds Moderna COVID-19 vaccine safe in adolescents
297 [GO] 2021―Aug―27 Janssen COVID-19 vaccine-related tinnitus and dizziness
298 [GO] 2021―Aug―27 Covid-19-vaccine-Pfizer-BioNTech
299 [GO] 2021―Aug―21 COVID-19 vaccination encouraged by the EMA/ECDC
300 [GO] 2021―Aug―21 Pfizer-BioNTech COVID-19 vaccine label update on Bell's palsy in Canada
301 [GO] 2021―Aug―21 Cerebral vein thrombosis after four COVID-19 vaccines in Europe
302 [GO] 2021―Aug―21 Covid-19-vaccine-pfizer-biontech
303 [GO] 2021―Aug―21 Covid-19-vaccine-Pfizer-BioNTech/prednisone
304 [GO] 2021―Aug―21 Remdesivir vs tocilizumab in COVID-19: adverse event profiles
305 [GO] 2021―Aug―13 NSAIDs do not increase risk or severity of COVID-19 infections
306 [GO] 2021―Aug―13 Cerebral venous sinus thrombosis after COVID-19 vaccination
307 [GO] 2021―Aug―13 Anaphylaxis after Pfizer-BioNTech COVID-19 vaccine in Japan
308 [GO] 2021―Aug―13 PRAC meeting 5 August 2021: COVID-19 vaccine safety issues
309 [GO] 2021―Aug―13 COVID-19-Vaccine-Pfizer-BioNTech
310 [GO] 2021―Aug―13 Covid-19-vaccine-pfizer-biontech
311 [GO] 2021―Aug―13 Covid-19-Vaccine-Pfizer-Biontech
312 [GO] 2021―Aug―13 Covid-19-vaccine-pfizer-biontech/levofloxacin
313 [GO] 2021―Aug―09 WHO GACVS reviews cases of GBS after COVID-19 vaccination
314 [GO] 2021―Aug―09 Rolling review of COVID-19 vaccine Vidprevtyn by EMA
315 [GO] 2021―Aug―09 Revisions of precautions for COVID-19 vaccines and other drugs in Japan
316 [GO] 2021―Aug―09 COVID-19-Vaccine-Pfizer-BioNTech
317 [GO] 2021―Aug―09 Covid-19-vaccine-pfizer-biontech
318 [GO] 2021―Aug―01 EMA assessing safety of anakinra in adults with COVID-19
319 [GO] 2021―Aug―01 PMDA: precautions should be revised for Covid-19 vaccine
320 [GO] 2021―Jul―23 Warning for Janssen COVID-19 vaccine: risk of Guillain-Barré syndrome
321 [GO] 2021―Jul―23 PRAC meeting highlights July 2021: Zynteglo and COVID-19 vaccines
322 [GO] 2021―Jul―23 COVID-19-Vaccine-Pfizer-BioNTech
323 [GO] 2021―Jul―23 Covid-19-vaccine-pfizer-biontech
324 [GO] 2021―Jul―17 AstraZeneca COVID-19 Vaccine-related risk of capillary leak syndrome
325 [GO] 2021―Jul―05 Myocarditis or pericarditis following COVID-19 vaccination
326 [GO] 2021―Jul―05 Thrombocytopenic purpura with AstraZeneca but not Pfizer-BioNTech COVID-19 vaccine
327 [GO] 2021―Jul―05 COVID-19-vaccine-pfizer-biontech
328 [GO] 2021―Jul―05 Covid-19-vaccines
329 [GO] 2021―Jun―26 FDA reports recall of Innova COVID-19 antigen rapid qualitative test
330 [GO] 2021―Jun―26 Myocarditis and pericarditis after COVID-19 vaccination
331 [GO] 2021―Jun―26 PRAC June 2021 meeting highlights: COVID-19 vaccine AEs
332 [GO] 2021―Jun―26 US-labelled supply of Moderna's COVID-19 vaccine in Cananda
333 [GO] 2021―Jun―18 Biological or targeted synthetic DMARDs increase COVID-19 severity
334 [GO] 2021―Jun―18 Pfizer-BioNtech's COVID-19 vaccine approved for younger adolescents
335 [GO] 2021―Jun―18 Safeguarding against use of contaminated COVID-19 Vaccine Janssen
336 [GO] 2021―Jun―18 Heterogeneity in potential COVID-19 vaccine-related AEs
337 [GO] 2021―Jun―18 EMA advice on COVID-19 vaccine-related thrombosis with thrombocytopenia
338 [GO] 2021―Jun―12 Nursing home resident deaths after Pfizer-BioNTech's COVID-19 vaccine
339 [GO] 2021―Jun―12 Many Danes with fever after COVID-19 vaccine would contact doctor
340 [GO] 2021―Jun―05 Methotrexate adversely affects immunogenicity to COVID-19 mRNA vaccines
341 [GO] 2021―Jun―05 Thrombocytopenia with Pfizer-BioNTech or Moderna COVID-19 vaccines
342 [GO] 2021―Jun―05 COVID-19-Vaccine-Pfizer-BioNTech/ocrelizumab
343 [GO] 2021―May―28 Bleeding and clotting with AstraZeneca's COVID-19 vaccine
344 [GO] 2021―May―28 Updated advice on thrombosis with thrombocytopenia syndrome and use of COVID-19 Vaccine AstraZeneca
345 [GO] 2021―May―21 COVID-19 vaccination during pregnancy: no increase in placental lesions
346 [GO] 2021―May―21 PRAC May 2021 meeting highlights: COVID-19 vaccine AEs
347 [GO] 2021―May―21 Do NSAIDs increase the severity of COVID-19?
348 [GO] 2021―May―14 COVID-19 vaccination errors in USA reported to ISMP
349 [GO] 2021―May―14 TTS with Janssen's COVID-19 vaccine
350 [GO] 2021―May―14 Anxiety disorders with Janssen's COVID-19 vaccine
351 [GO] 2021―May―14 AstraZeneca COVID-19 vaccine-related thromboembolism
352 [GO] 2021―May―14 AstraZeneca and Pfizer-BioNTech COVID-19 vaccines: AEs in South Korea
353 [GO] 2021―May―07 No evidence of TTS risk with Pfizer/BioNTech's COVID-19 vaccine
354 [GO] 2021―May―07 FDA and CDC recommend resuming use of Janssen COVID-19 vaccine
355 [GO] 2021―May―07 COVID-19 vaccine adverse events reported via app
356 [GO] 2021―May―07 AstraZeneca COVID-19 vaccine recommended in ≥50s in Australia
357 [GO] 2021―May―07 New EMA/ECDC initiative for monitoring COVID-19 vaccines
358 [GO] 2021―May―03 PRAC: blood clots with Janssen's COVID-19 vaccine
359 [GO] 2021―May―03 Canadian findings on AstraZeneca COVID-19 Vaccine and COVISHIELD
360 [GO] 2021―Apr―23 FDA remote evaluation of drug manufacturing during COVID-19
361 [GO] 2021―Apr―23 Health Canada: blood clots with AstraZeneca's COVID-19 vaccine
362 [GO] 2021―Apr―23 Denmark ceases roll out of AstraZeneca's COVID-19 vaccine
363 [GO] 2021―Apr―23 COVID-19 Vaccine Janssen: rare unusual blood clots, low platelets
364 [GO] 2021―Apr―23 PRAC: blood clots or capillary leak syndrome with COVID-19 vaccines
365 [GO] 2021―Apr―23 Health Canada: AKI or ARF with remdesivir for COVID-19?
366 [GO] 2021―Apr―16 Should cancer patients receiving ICIs received COVID-19 vaccination?
367 [GO] 2021―Apr―16 Pfizer-BioNTech COVID-19 vaccine: AEs after vaccination in New Zealand
368 [GO] 2021―Apr―16 AstraZeneca COVID-19 vaccine: thrombosis with thrombocytopenia
369 [GO] 2021―Apr―10 Falsified COVID-19 vaccine recently identified in Mexico
370 [GO] 2021―Apr―10 AstraZeneca COVID-19 vaccine: EMA continues review of rare blood clots
371 [GO] 2021―Apr―10 AstraZeneca COVID-19 vaccine: no increased rate of VTE
372 [GO] 2021―Apr―02 No increased risk of anaphylaxis with AstraZeneca COVID-19 vaccine
373 [GO] 2021―Apr―02 Ongoing evaluation of COVID-19 Vaccine AstraZeneca-related blood clots
374 [GO] 2021―Apr―02 AstraZeneca COVID-19 vaccine not recommended in adults under 55 in Canada
375 [GO] 2021―Mar―26 Universal COVID-19 vaccination cost saving unless anaphylaxis rate high
376 [GO] 2021―Mar―26 Anaphylaxis in Australia with AstraZeneca's COVID-19 vaccine
377 [GO] 2021―Mar―26 Benefits of COVID-19 Vaccine AstraZeneca outweigh risks of blood clots
378 [GO] 2021―Mar―26 March 2021 PRAC meeting highlights include COVID-19 vaccine update
379 [GO] 2021―Mar―26 COVID-19-vaccine-Pfizer-BioNTech
380 [GO] 2021―Mar―19 COVID-19 mRNA vaccines: acute allergic reaction and anaphylaxis
381 [GO] 2021―Mar―19 Reports of flu-like symptoms after COVID-19 vaccination
382 [GO] 2021―Mar―19 EMA assessing cases of blood clots after AstraZeneca COVID-19 vaccine
383 [GO] 2021―Mar―19 COVID-19 vaccine AE reports in Australia and New Zealand
384 [GO] 2021―Mar―13 Vial and carton labelling updated for Moderna COVID-19 vaccine
385 [GO] 2021―Mar―13 COVID-19 vaccine-related lymphadenopathy may affect breast screening
386 [GO] 2021―Feb―26 COVID-19 vaccine safety monitoring
387 [GO] 2021―Feb―19 Second HPRA safety update on COVID-19 vaccines
388 [GO] 2021―Feb―12 MHRA Yellow Card reports on COVID-19 vaccine adverse reactions
389 [GO] 2021―Feb―12 Safety update on COVID-19 vaccine Comirnaty finds no new concerns
390 [GO] 2021―Feb―05 Withdrawal of ACEIs or ARBs in hospitalised patients with COVID-19
391 [GO] 2021―Feb―05 WHO considers Pfizer BioNTech COVID-19 vaccine safe in elderly
392 [GO] 2021―Feb―05 HPRA safety update on BioNTech and Moderna COVID-19 vaccines
393 [GO] 2021―Jan―29 Norway advised to assess the very frail prior to COVID-19 vaccination
394 [GO] 2021―Jan―29 Moderna COVID-19 vaccine: 2.5 cases of anaphylaxis per million doses
395 [GO] 2021―Jan―29 ISMP reports: errors or hazards with COVID-19 vaccines
396 [GO] 2021―Jan―29 NSAID use does not increase risk of COVID-19-related death
397 [GO] 2021―Jan―22 Deaths in frail patients after Pfizer/BioNTech COVID-19 vaccination
398 [GO] 2021―Jan―22 Advice on COVID-19 vaccines approved in UK by MHRA
399 [GO] 2021―Jan―22 Safety of COVID-19 vaccines: who should see an allergist
400 [GO] 2021―Jan―21 Pfizer-BioNTech COVID-19 vaccine-related risk of anaphylaxis
401 [GO] 2021―Jan―08 Pfizer COVID-19-related drug use and safety surveillance
402 [GO] 2021―Jan―06 Managing allergic reactions to Pfizer-BioNTech COVID-19 vaccine
403 [GO] 2020―Dec―21 COVID-19-related deaths not increased with ACE inhibitor or ARB use
404 [GO] 2020―Dec―11 EMA and ICMRA urge continuation of COVID-19 vaccine safety trials
405 [GO] 2020―Nov―27 EMA's safety monitoring plan for COVID-19 vaccines
406 [GO] 2020―Nov―20 Drug-drug interactions in patients with COVID-19
407 [GO] 2020―Nov―13 EMA guidance on risk management plans for COVID-19 vaccines reviewed
408 [GO] 2020―Nov―06 Quality of ADR reporting evaluated for remdesivir trials of COVID-19
409 [GO] 2020―Nov―06 Hydroxychloroquine-related psychiatric disorders in COVID-19 patients
410 [GO] 2020―Nov―06 Phase III trial of Covid-19 treatment paused for safety concerns
411 [GO] 2020―Nov―06 Concerns raised with MHRA of anticoagulant use during pandemic
412 [GO] 2020―Oct―16 Remdesivir-related acute kidney injury in patients with COVID-19
413 [GO] 2020―Oct―02 Sex differences in ADR reports for drugs used to treat COVID-19
414 [GO] 2020―Aug―14 Proton pump inhibitors increase risk of COVID-19
415 [GO] 2020―Aug―14 Health Canada approves first drug for treatment of COVID-19
416 [GO] 2020―Jul―24 Risk of bradycardia with lopinavir/ritonavir in COVID-19 patients
417 [GO] 2020―Jul―17 Meta-analysis: RAAS inhibitors and COVID-19 positivity and/or mortality
418 [GO] 2020―Jun―26 New potential interaction with emergency COVID-19 medicine remdesivir
419 [GO] 2020―Jun―12 Benefit-risk assessment for remdesivir in COVID-19
420 [GO] 2020―Jun―12 Risks of chloroquine or hydroxychloroquine use for COVID-19
421 [GO] 2020―Jun―05 COVID-19 pregnancy prevention guidance on teratogenic drugs
422 [GO] 2020―Jun―05 UK's MHRA publishes guidance for valproate PPP during pandemic
423 [GO] 2020―May―29 Chloroquine and hydroxychloroquine increase risk of death in COVID-19
424 [GO] 2020―May―29 Serious cardiac AEs with hydroxychloroquine during COVID-19 pandemic
425 [GO] 2020―May―29 Cardiac adverse reactions with off-label Covid-19 treatments
426 [GO] 2020―May―23 US guidance issued for postmarketing AE reporting during pandemic
427 [GO] 2020―May―18 International Society of Pharmacovigilance: COVID-19 role
428 [GO] 2020―May―18 MHRA COVID-19 website for reporting ADRs and incidents
429 [GO] 2020―May―18 Risk of Covid-19 with renin-angiotensin-aldosterone system medications
430 [GO] 2020―May―11 Evaluation of potential therapies for COVID-19 global pandemic
431 [GO] 2020―May―11 Demand for potentially hazardous COVID-19 treatments
432 [GO] 2020―May―11 UMC: use appropriate COVID-19-related terms for ICSRs
433 [GO] 2020―May―04 ACEI inhibitors and ARBs do not increase severity of COVID-19
434 [GO] 2020―May―04 Safety concerns with higher dosage chloroquine in COVID-19 patients
435 [GO] 2020―May―04 High incidence of ADRs in COVID-19 patients in China
436 [GO] 2020―May―04 Antimalarial use in COVID-19 patients requires close monitoring
437 [GO] 2020―Apr―20 EMA: continue use of ACE inhibitors, sartans during COVID-19 pandemic
438 [GO] 2020―Apr―06 Regulatory agencies issue advice on use of NSAIDs for COVID-19

438 Results       Page 1


Last change 2022―Feb―03 17:06:14 UTC

© Daten-Quadrat 2022       Done in 0.010 sec